Healthcare provider profile · identity verified

Jack C Evans, MD

Allopathic & Osteopathic Physicians|Family Medicine · LAUREL, MS · NPI 1396784187

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jack C Evans, MD received $144.09 in general payments during 2025 across 8 reported records.

Novo Nordisk Inc accounted for 40.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Farxiga by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Xarelto by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$144.09

8 reported records · 5 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$57.78	40.1%	3	2025
Bayer Healthcare Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$35.86	24.9%	2	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$22.07	15.3%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$14.55	10.1%	1	2025
Inspire Medical Systems, Inc.	Unresolved — no canonical attribution shown	$13.83	9.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$144.09	8

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Kerendia Normalized: kerendia	Drug	Bayer Healthcare Pharmaceuticals Inc.	$35.86	2	2025
Source payment records 2025-02-26 · Bayer Healthcare Pharmaceuticals Inc. · $19.39 · Open Payments source 2025-10-22 · Bayer Healthcare Pharmaceuticals Inc. · $16.47 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$22.07	1	2025
Source payment records 2025-09-09 · Janssen Pharmaceuticals, Inc · $22.07 · Open Payments source
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$14.55	1	2025
Source payment records 2025-03-26 · AstraZeneca Pharmaceuticals LP · $14.55 · Open Payments source
INSPIRE Normalized: inspire	Device	Inspire Medical Systems, Inc.	$13.83	1	2025
Source payment records 2025-07-08 · Inspire Medical Systems, Inc. · $13.83 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	223	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	223	64
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	XARELTO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970	Xarelto · 2024 Exact normalized brand match · 1 Part D row	51	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	109	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	602	160
Amlodipine Besylate	Amlodipine Besylate	507	131
Pantoprazole Sodium	Pantoprazole Sodium	500	122
Atorvastatin Calcium	Atorvastatin Calcium	481	116
Levothyroxine Sodium	Levothyroxine Sodium	449	112
Metoprolol Succinate	Metoprolol Succinate	412	100
Trazodone Hcl	Trazodone Hcl	384	111
Omeprazole	Omeprazole	363	96
Duloxetine Hcl	Duloxetine Hcl	356	70
Losartan Potassium	Losartan Potassium	315	89
Metformin Hcl	Metformin Hcl	310	76
Bupropion Xl	Bupropion Hcl	303	88
Gabapentin	Gabapentin	301	83
Citalopram Hbr	Citalopram Hydrobromide	251	74
Hydrochlorothiazide	Hydrochlorothiazide	247	65
Farxiga	Dapagliflozin Propanediol	223	64
Sertraline Hcl	Sertraline Hcl	220	57
Tamsulosin Hcl	Tamsulosin Hcl	207	60
Glimepiride	Glimepiride	201	47
Meloxicam	Meloxicam	184	51
Potassium Chloride	Potassium Chloride	181	52
Alendronate Sodium	Alendronate Sodium	175	42
Irbesartan	Irbesartan	174	45
Allopurinol	Allopurinol	167	55
Diclofenac Sodium	Diclofenac Sodium	163	48
Valsartan	Valsartan	158	34
Spironolactone	Spironolactone	156	35
Pravastatin Sodium	Pravastatin Sodium	150	42
Donepezil Hcl	Donepezil Hcl	139	49
Lisinopril	Lisinopril	139	42
Metformin Hcl Er	Metformin Hcl	138	43
Fluticasone Propionate	Fluticasone Propionate	131	61
Furosemide	Furosemide	127	40
Montelukast Sodium	Montelukast Sodium	126	39
Mounjaro	Tirzepatide	113	27
Synthroid	Levothyroxine Sodium	110	24
Eliquis	Apixaban	109	30
Ozempic	Semaglutide	109	17
Ibandronate Sodium	Ibandronate Sodium	104	44
Ezetimibe	Ezetimibe	101	32
Clopidogrel	Clopidogrel Bisulfate	95	28
Simvastatin	Simvastatin	94	23
Escitalopram Oxalate	Escitalopram Oxalate	93	21
Zolpidem Tartrate	Zolpidem Tartrate	92	25
Olmesartan Medoxomil	Olmesartan Medoxomil	90	24
Carvedilol	Carvedilol	89	28
Buspirone Hcl	Buspirone Hcl	87	19
Prednisone	Prednisone	85	36
Temazepam	Temazepam	82	14
Famotidine	Famotidine	80	24
Fenofibrate	Fenofibrate	80	15
Amitriptyline Hcl	Amitriptyline Hcl	78	23
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	77	29
Pioglitazone Hcl	Pioglitazone Hcl	71	16
Venlafaxine Hcl Er	Venlafaxine Hcl	71	16
Esomeprazole Magnesium	Esomeprazole Magnesium	69	22
Ropinirole Hcl	Ropinirole Hcl	68	20
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	65	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	14
Celecoxib	Celecoxib	62	22
Jardiance	Empagliflozin	55	19
Oxybutynin Chloride	Oxybutynin Chloride	55	19
Tresiba Flextouch U-100	Insulin Degludec	55	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	53	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	52	15
Benazepril Hcl	Benazepril Hcl	51	suppressed
Xarelto	Rivaroxaban	51	suppressed
Memantine Hcl	Memantine Hcl	50	16
Clonazepam	Clonazepam	49	17
Clonidine Hcl	Clonidine Hcl	48	17
Nebivolol Hcl	Nebivolol Hcl	48	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	47	15
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	47	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	15
Sucralfate	Sucralfate	45	17
Aripiprazole	Aripiprazole	44	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	44	13
Tramadol Hcl	Tramadol Hcl	44	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	11
Finasteride	Finasteride	43	14
Tizanidine Hcl	Tizanidine Hcl	42	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	41	14
Atenolol	Atenolol	39	13
Bupropion Hcl Sr	Bupropion Hcl	39	suppressed
Methylprednisolone	Methylprednisolone	39	36
Pregabalin	Pregabalin	39	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	38	suppressed
Fluconazole	Fluconazole	37	15
Metoprolol Tartrate	Metoprolol Tartrate	35	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Mirtazapine	Mirtazapine	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	34	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	33	suppressed
Alprazolam	Alprazolam	32	15
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Cephalexin	Cephalexin	30	20
Myrbetriq	Mirabegron	30	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	26
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Propranolol Hcl Er	Propranolol Hcl	28	suppressed
Nabumetone	Nabumetone	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	11
Doxycycline Hyclate	Doxycycline Hyclate	26	25
Triamcinolone Acetonide	Triamcinolone Acetonide	25	19
Acyclovir	Acyclovir	24	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	24	suppressed
Sotalol	Sotalol Hcl	24	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	23	suppressed
Ondansetron Odt	Ondansetron	22	11
Shingrix	Varicella-Zoster Ge/As01b/Pf	22	14
Lansoprazole	Lansoprazole	21	suppressed
Methocarbamol	Methocarbamol	21	12
Nifedipine Er	Nifedipine	21	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	21	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	18
Testosterone Cypionate	Testosterone Cypionate	20	suppressed
Torsemide	Torsemide	20	suppressed
Vraylar	Cariprazine Hcl	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Trintellix	Vortioxetine Hydrobromide	19	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	18	suppressed
Mupirocin	Mupirocin	18	11
Nystatin	Nystatin	18	suppressed
Azithromycin	Azithromycin	17	16
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	16	suppressed
Ramipril	Ramipril	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Indapamide	Indapamide	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Linzess	Linaclotide	13	suppressed
Metolazone	Metolazone	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	11
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Victoza 3-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$144.09 · 8 records	Novo Nordisk Inc	FARXIGA, INSPIRE, Kerendia, SPRAVATO	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error